Rezafungin Could Prevent Fungal Infections in Transplant Patients
A new weekly drug shows promise for adults receiving stem cell transplants by offering a potential alternative to daily regimens.
Updated on Oct. 22, 2026 in Diseases — General
Live Poll
Do you believe new pharmaceutical trials for rare diseases prioritize patient safety over potential profit?
Phase III clinical trial results show that the investigational drug rezafungin may effectively prevent invasive fungal diseases in adults undergoing allogeneic haematopoietic stem cell transplantation. The study met its primary endpoint of non-inferiority compared to standard antimicrobial care.
Why it matters
Patients undergoing allogeneic stem cell transplants are at significant risk for life-threatening fungal infections, making the development of effective prophylaxis critical. This study offers a potential new option for these high-risk patients currently awaiting regulatory review.
In a Phase III trial of 602 patients, researchers compared rezafungin to standard antimicrobial therapy for fungal disease prophylaxis. The study demonstrated non-inferiority, with a 60.7% fungal-free survival rate in the rezafungin arm versus 59.0% for the standard regimen.
The players
Mundipharma
A pharmaceutical company that develops and markets various medications and is the sponsor of the rezafungin clinical trials.
FDA
The United States government agency responsible for protecting public health through the regulation of food, pharmaceuticals, and medical devices.
EMA
An agency of the European Union responsible for the scientific evaluation and supervision of medicines for human and veterinary use.
The details
Rezafungin is administered intravenously, with a 400 mg loading dose followed by a 200 mg weekly maintenance dose. This delivery method differs from the standard daily oral azole and trimethoprim/sulfamethoxazole regimen typically used following stem cell engraftment. Researchers observed serious adverse events in 66.0% of the rezafungin group and 67.5% of the standard regimen group during the study.
Timeline
April 2026: Topline ReSPECT trial results were announced.
October 22, 2026: Phase III ReSPECT trial results were presented at IDWeek.
Q1 2027: The FDA has a target action date for the drug's regulatory review.
Health Landscape
Current prophylaxis for invasive fungal diseases relies heavily on daily oral regimens for patients undergoing high-risk stem cell procedures. The ReSPECT clinical trial program introduces a weekly intravenous alternative to the standard of care.
Patients preparing for allogeneic stem cell transplantation should consult their hematologist or transplant specialist about the status of new prophylactic therapies. These trials are critical for managing the high risk of fungal infection, and any changes to care should be discussed with a doctor.
The takeaway
Ongoing clinical trials continue to investigate new methods for reducing the burden of invasive fungal disease during stem cell recovery. Patients should maintain awareness of upcoming drug approvals by following the FDA target action dates for their specific condition.
What happens next
The FDA is expected to complete its regulatory review of rezafungin by Q1 2027.
Further reading
For broader context on clinical developments for immunocompromised populations, visit Diseases — General.
More information
Review the clinical profile and regulatory status in the FDA prescribing information for REZZAYO.
Live Poll
Do you believe new pharmaceutical trials for rare diseases prioritize patient safety over potential profit?
